Compare Pinterest Inc (PINS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pinterest Inc vs TG Therapeutics Inc — how do they compare? Pinterest Inc trades at $22.54 (market cap $12.79B), while TG Therapeutics Inc trades at $52.7 (market cap $8.26B). The key difference: Pinterest Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Pinterest Inc nearer its low. Which is the better fit depends on your goals.
| PINS | TGTX | |
|---|---|---|
Market Cap | $12.79B | $8.26B |
Sector | Media | Health |
52-Week High | $39.17 | $59.06 |
52-Week Low | $15.42 | $26.39 |
Enterprise Value | $12.69B | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pinterest (PINS) trades at $22.835, down 1.57% on the day, with a bullish technical outlook driven by moving averages and a consensus analyst price target of $27.53. Revenue grew to $4.22B in 2025, with net income turning positive at $416.86M, though Q2 2026 earnings are pending. Recent news highlights focus on user growth and e-commerce integration, while insider sales and cash flow trends warrant monitoring.
The stock presents upside potential from strong analyst buy ratings and revenue expansion, but risks include negative net cash flow, high valuation multiples, and competitive pressures in social media. Investor sentiment is cautiously optimistic ahead of Q2 earnings, with institutional activity showing mixed signals.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Pinterest Inc
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
